The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis

Clinical Endocrinology

Volumn 78, Issue 6, 2013, Pages 844-851

  Yamada, Shunsuke ^a   Tsuruya, Kazuhiko ^a   Yoshida, Hisako ^a   Taniguchi, Masatomo ^a   Haruyama, Naoki ^a   Tanaka, Shigeru ^a   Eriguchi, Masahiro ^a   Nakano, Toshiaki ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CINACALCET; CREATININE; ESTROGEN; N TERMINAL CROSS LINKING TELOPEPTIDE OF TYPE 1 COLLAGEN; NITROGEN; PARATHYROID HORMONE; PHOSPHATE; RALOXIFENE; TARTARIC ACID DERIVATIVE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; UREA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; HYPOCALCEMIA; MALE; OSTEOLYSIS; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; UREA BLOOD LEVEL; VITAMIN D DEFICIENCY;

ACID PHOSPHATASE; ACUTE KIDNEY INJURY; ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; ISOENZYMES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PEPTIDES; PERITONEAL DIALYSIS; RALOXIFENE; REGRESSION ANALYSIS;

EID: 84876513429     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12070     Document Type: Article

References (35)

1. Moe, S., Drüeke, T., Lameire, N., et al,. (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Advances in Chronic Kidney Disease, 14, 3-12.
2. Moe, S., Drüeke, T., Cunningham, J., et al,. (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (K/DIGO). Kidney International, 69, 1945-1953.
3. Kidney Disease: Improving Global Outcome (K/DIGO) Work Group. (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, 76 (Suppl), S1-S130.
4. Schulz, E., Affai, K., Liu, X., et al,. (2004) Aortic calcification and the risk of osteoporosis and fractures. Journal of Clinical Endocrinology and Metabolism, 89, 4246-4253.
5. Manghat, P., Souleimanova, I., Cheung, J., et al,. (2011) Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone, 48, 1127-1132.
6. London, G.M., Marty, C., Marchais, S.J., et al,. (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. Journal of the American Society of Nephrology, 15, 1943-1951.
7. Schwarz, C., Sulzbacher, I., &, Oberbauer, R., (2006) Diagnosis of renal osteodystrophy. European Journal of Clinical Investigation, 36, S13-S22.
8. Singer, F.R., &, Eyre, D.R., (2008) Using biochemical markers of bone turnover in clinical practice. Cleveland Clinic Journal of Medicine, 75, 739-750.
9. Gundberg, C.M., &, Nishimoto, S.K., (1999) Dynamics of bone and cartilage metabolism; principles and clinical applications. In:, M. J. Seibel, ed. Vitamin K Dependent Proteins of Bone and Cartilage, Academic Press, San Diego, 43-58.
10. Colwell, A., &, Eastell, R., (1996) The renal clearance of free and conjugated pyridinium cross-links of collagen. Journal of Bone and Mineral Research, 11, 1976-1980.
11. Delmas, P.D., Wilson, D.M., Mann, K.G., et al,. (1983) Effect of renal function on plasma levels of bone Gla-protein. Journal of Clinical Endocrinology and Metabolism, 57, 1028-1030.
12. Gundberg, C.M., &, Clough, M.E., (1992) The osteocalcin propeptide is not secreted in vitro or in vivo. Journal of Bone and Mineral Research, 7, 73-80.
13. Alvarez, L., Torregrosa, J.V., Peris, P., et al,. (2004) Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. Journal of Bone and Mineral Metabolism, 22, 254-259.
14. Halleen, J.M., Alatalo, S.L., Janckila, A.J., et al,. (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clinical Chemistry, 47, 597-600.
15. Hannon, R.A., Clowes, J.A., Eagleton, A.C., et al,. (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone, 34, 187-194.
16. Halleen, J.M., Ylipahkala, H., Alatalo, S.L., et al,. (2002) Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcified Tissue International, 71, 20-25.
17. Halleen, J.M., Hentunen, T.A., Karp, M., et al,. (1998) Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. Journal of Bone and Mineral Research, 13, 683-687.
18. Yamada, S., Inaba, M., Kurajoh, M., et al,. (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP) 5b as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clinical Endocrinology, 69, 189-196.
19. Shidara, K., Inaba, M., Okuno, S., et al,. (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcified Tissue International, 82, 278-287.
20. Chu, P., Chao, T.Y., Lin, Y.F., et al,. (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase 5b in uremic patients on maintenance hemodialysis. American Journal of Kidney Diseases, 541, 1052-1059.
21. Working Group Committee for the Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy. (2010) 2009 Japanese Society for Dialysis Therapy Guidelines for Peritoneal Dialysis. The Apher Dial, 14, 489-504.
22. Payne, R.B., Little, A.J., Williams, R.B., et al,. (1973) Interpretation of serum calcium in patients with abnormal serum proteins. British Medical Journal, 15, 643-646.
23. Maclure, M., &, Greenland, S., (1992) Test for trend and dose-response: misinterpretations and alternatives. American Journal of Epidemiology, 135, 96-104.
24. Nishizawa, Y., Inaba, M., Ishii, M., et al,. (2008) Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. Journal of Bone and Mineral Metabolism, 26, 265-270.
25. Scariano, J.K., Glew, R.H., Bou-Serhal, C.E., et al,. (1998) Serum levels of cross-linked N telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone, 23, 471-477.
26. van Straalen, J.P., Sanders, E., Prummel, M.F., et al,. (1991) Bone alkaline phosphate as indicator of bone formation. Clinica Chimica Acta, 201, 27-34.
27. Kaida, H., Ishibashi, M., Nishida, H., et al,. (2005) Usefulness of whole PTH assay in patients with renal osteodystrophy-correlation with bone scintigraphy. Annals of Nuclear Medicine, 19, 179-184.
28. Mochizuki, Y., Nishizawa, Y., Oishi, A., et al,. (2005) Day-to-day and diurnal variations of serum tartrate-resistant acid phosphatase type 5b with newly developed TRACP5b kit and their comparison to other bone resorption markers. Bone (NY), 36, S334.
29. Souberbielle, J.C., Roth, H., &, Fouque, D.P., (2010) Parathyroid hormone measurement in CKD. Kidney International, 77, 93-100.
30. Sherrard, D.J., Hercz, G., Pei, Y., et al,. (1993) The spectrum of bone disease in end stage renal failure-an evolving disorder. Kidney International, 43, 436-442.
31. Iwasaki, Y., Yamato, H., Nii-Kono, T., et al,. (2006) Insufficiency of PTH action on bone in uremia. Kidney International, 70, S34-S36.
32. Fukagawa, M., Kazama, J.J., &, Kurokawa, K., (2002) Renal osteodystrophy and secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 17, S2-S5.
33. Barreto, F.C., Barreto, D.V., Moysés, R.M., et al,. (2008) K/DOQI recommended serum PHT level do not prevent low turnover bone in hemodialysis patients. Kidney International, 73, 771-777.
34. Gordon, P.L., &, Frasse, L.A., (2010) Management of osteoporosis in CKD stages 3 to 5. American Journal of Kidney Diseases, 55, 941-956.
35. Gerdhem, P,., Ivaska, K.K., Alatalo, S.L., et al,. (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly woman. Journal of Bone and Mineral Research, 19, 386-393.